患有耐药性的儿科患者的神经刺激:一步一步的视频
Santiago E Cicutti1, Guido P Gromadzyn1, Javier F Cuello2
1Department of Neurosurgery, Juan P. Garrahan Hospital, Buenos Aires, Argentina; and.
Neurosurgical focus: Video
|July 3, 2024
概括
神经刺激 (VNS) 为耐火性提供了一种安全的神经调节治疗方法. 这个教育视频详细介绍了VNS设备的手术植入程序.
科学领域:
- 神经外科 神经外科
- 神经调节是一种神经调节.
- 的治疗方法 治疗
背景情况:
- 迷走神经刺激 (VNS) 是一种成熟的耐性的辅助疗法.
- 它涉及通过植入装置对迷走神经进行慢性电刺激.
- VNS适用于无法接受或不响应切除手术的患者.
研究的目的:
- 为VNS植入提供详细,逐步的手术教程.
- 为执行VNS手术的外科医生提供教育资源.
- 为了说明VNS设备放置的技术方面.
主要方法:
- 手术植入VNS装置,包括在迷走神经周围放置,并创建发电机口袋.
- 详细的程序步骤在附带的视频中展示.
- 专注于手术技术,以实现最佳的器械放置和患者选择.
主要成果:
- 本视频提供了关于VNS植入手术的全面指南.
- 植入VNS通常耐受良好,副作用极少.
- 该程序在技术上是可行的,用于耐火性的管理.
结论:
- 这个教育视频是VNS手术植入的宝贵资源.
- 对于难以治疗的患者来说,VNS仍然是一个关键的治疗选择.
- 掌握手术技术对于成功的VNS治疗至关重要.
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
284
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
284
Antiepileptic Drugs: Potassium Channel Activators
165
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
165


